{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:21:04Z","timestamp":1767374464798,"version":"3.44.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ahj.2003.10.034","type":"journal-article","created":{"date-parts":[[2004,4,9]],"date-time":"2004-04-09T05:21:41Z","timestamp":1081488101000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data"],"prefix":"10.1016","volume":"147","author":[{"given":"Henry R","family":"Black","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2003.10.034_BIB1","unstructured":"Heart and stroke facts: 2002 statistical supplement. Dallas, Tex: American Heart Association; 2001"},{"key":"10.1016\/j.ahj.2003.10.034_BIB2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2003.10.034_BIB3","first-page":"9","article-title":"1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension","volume":"8","year":"1999","journal-title":"Blood Press"},{"key":"10.1016\/j.ahj.2003.10.034_BIB4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/archinte.162.2.131","article-title":"Reflections on hypertension control rates","volume":"162","author":"Lenfant","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2003.10.034_BIB5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2003.10.034_BIB6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0895-7061(98)00060-0","article-title":"The role of combination therapy in the treatment of hypertension","volume":"11","author":"Moser","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB7","series-title":"Goodman and Gilman's the pharmacological basis of therapeutics","first-page":"809","article-title":"Renin and angiotensin","author":"Jackson","year":"2001"},{"key":"10.1016\/j.ahj.2003.10.034_BIB8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200208000-00002","article-title":"Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system","volume":"20","author":"Young","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","article-title":"Aldosterone as a mediator in cardiovascular injury","volume":"10","author":"Stier","year":"2002","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ahj.2003.10.034_BIB10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Mechanisms of disease","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2003.10.034_BIB11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1440-1681.2001.03523.x","article-title":"New perspectives on the role of aldosterone excess in cardiovascular disease","volume":"28","author":"Stowasser","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003495-200262050-00001","article-title":"Rationale for the use of aldosterone antagonists in congestive heart failure","volume":"62","author":"Rocha","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ahj.2003.10.034_BIB13","first-page":"709","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"Randomized Aldactone Evaluation Study Investigators. N Engl J Med"},{"key":"10.1016\/j.ahj.2003.10.034_BIB14","first-page":"233","article-title":"Influence of beta-blockade on aldosterone metabolism under normal and low sodium diet in man","volume":"27","author":"Plouin","year":"1977","journal-title":"Biomedicine"},{"key":"10.1016\/j.ahj.2003.10.034_BIB15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","article-title":"Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors","volume":"33","author":"Borghi","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","article-title":"Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats","volume":"40","author":"Naruse","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ahj.2003.10.034_BIB20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1291\/hypres.23.25","article-title":"Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients","volume":"23","author":"Sato","year":"2000","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1071-9164(96)80009-1","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibition therapy in chronic heart failure","volume":"2","author":"Struthers","year":"1996","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2003.10.034_BIB22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricle in humans","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB23","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2003.10.034_BIB24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/jme.0.0240321","article-title":"Expression of 11\u03b2-hydroxylase and aldosterone synthase genes in the rat brain","volume":"24","author":"MacKenzie","year":"2000","journal-title":"J Mol Endocrinol"},{"issue":"Suppl N","key":"10.1016\/j.ahj.2003.10.034_BIB25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/16.suppl_N.92","article-title":"Aldosterone","volume":"16","author":"Bonvalet","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2003.10.034_BIB26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/ajh\/7.1.100","article-title":"Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells","volume":"7","author":"Kornel","year":"1994","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0006-8993(85)91291-0","article-title":"Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro","volume":"361","author":"Coirini","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.RES.76.6.973","article-title":"Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells","volume":"76","author":"Wehling","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","article-title":"The role of 11-\u03b2-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries","volume":"35","author":"Alzamora","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"10.1016\/j.ahj.2003.10.034_BIB31","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00004872-199512010-00054","article-title":"Albuminuria in untreated patients with primary aldosteronism or essential hypertension","volume":"13","author":"Halimi","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","article-title":"Cardiovascular complications in patients with primary aldosteronism","volume":"33","author":"Nishimura","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ahj.2003.10.034_BIB33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","article-title":"Changes in left ventricular anatomy and function in hypertension and primary aldosteronism","volume":"27","author":"Rossi","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB34","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.jhh.1000590","article-title":"Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension","volume":"12","author":"Fagard","year":"1998","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB36","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0002-9149(00)00728-1","article-title":"Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects","volume":"85","author":"Schlaich","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/hrt.77.1.24","article-title":"Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass","volume":"77","author":"Schunkert","year":"1997","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2003.10.034_BIB38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11906-001-0049-z","article-title":"Role of central mineralocorticoid receptors in cardiovascular disease","volume":"3","author":"Gomez-Sanchez","year":"2001","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ahj.2003.10.034_BIB39","first-page":"1583","article-title":"Vasoconstrictor effects of aldosterone in isolated vascular tissue","volume":"4","author":"Purdy","year":"1982","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.RES.37.5.569","article-title":"Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats","volume":"37","author":"Reid","year":"1975","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","article-title":"Chronic administration of aldosterone depresses baroreceptor reflex function in the dog","volume":"24","author":"Wang","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB43","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2003.10.034_BIB44","first-page":"E657","article-title":"Determinants of cardiac fibrosis in experimental hypermineralocorticoid states","volume":"269","author":"Young","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","article-title":"Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats","volume":"17","author":"Benetos","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans","volume":"103","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Colch)"},{"key":"10.1016\/j.ahj.2003.10.034_BIB47","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2003.10.034_BIB48","first-page":"316","article-title":"Vascular aldosterone","volume":"269","author":"Hatakeyama","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2003.10.034_BIB49","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","article-title":"Myocardial production of aldosterone and corticosterone in the rat","volume":"273","author":"Silvestre","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ahj.2003.10.034_BIB50","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1210\/endo.138.8.5326","article-title":"Aldosterone biosynthesis in the rat brain","volume":"138","author":"Gomez-Sanchez","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2003.10.034_BIB51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/07435800009048566","article-title":"Corticosteroid production by fetal rat hippocampal neurons","volume":"26","author":"MacKenzie","year":"2000","journal-title":"Endocr Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0039-128X(94)00004-V","article-title":"Mineralocorticoid modulation of central control of blood pressure","volume":"60","author":"Gomez-Sanchez","year":"1995","journal-title":"Steroids"},{"key":"10.1016\/j.ahj.2003.10.034_BIB53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","volume":"25","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.ahj.2003.10.034_BIB55","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","article-title":"Reactive and reparative myocardial fibrosis in arterial hypertension in the rat","volume":"26","author":"Brilla","year":"1992","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB56","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/jmcc.1997.0612","article-title":"Myocardial fibrosis associated with aldosterone or angiotensin administration","volume":"30","author":"Ramires","year":"1998","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0008-6363(96)88542-7","article-title":"Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, an aldosterone antagonist","volume":"29","author":"Van Belle","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spironolactone derivatives","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ahj.2003.10.034_BIB61","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","article-title":"Effect of a selective aldosterone receptor antagonist in myocardial infarction","volume":"281","author":"Delyani","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2 part 2","key":"10.1016\/j.ahj.2003.10.034_BIB62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB63","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","article-title":"Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries","volume":"104","author":"Ward","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB65","first-page":"52","article-title":"Aldosterone antagonists in hypertension and heart failure","volume":"61","author":"Mantero","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ahj.2003.10.034_BIB66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB67","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ahj.2003.10.034_BIB69","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2003.10.034_BIB70","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB72","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"issue":"4 Suppl 1","key":"10.1016\/j.ahj.2003.10.034_BIB73","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ahj.2003.10.034_BIB74","doi-asserted-by":"crossref","unstructured":"Pitt B, Reichek N, Willenbrock R, et al. The effects of eplerenone, enalapril and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-LVH study. Circulation 2003 (in press)","DOI":"10.1016\/j.accreview.2003.12.043"},{"key":"10.1016\/j.ahj.2003.10.034_BIB75","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2003.10.034_BIB76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00126097-200308000-00006","article-title":"Methods for evaluating the duration of action of once-daily antihypertensive therapy","volume":"8","author":"Myers","year":"2003","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.ahj.2003.10.034_BIB77","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker, eplerenone, using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2003.10.034_BIB78","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the highly selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in older patients with systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2003.10.034_BIB79","doi-asserted-by":"crossref","unstructured":"Burgess E, Ruilope LM, Francischetti E, et al. Efficacy and safety of adding a second antihypertensive agent to eplerenone in patients with essential hypertension [abstract]. Eighteenth Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 14\u201317, 2003, New York, NY","DOI":"10.1016\/S0895-7061(03)00358-3"},{"key":"10.1016\/j.ahj.2003.10.034_BIB80","doi-asserted-by":"crossref","unstructured":"Willenbrock R, van Mieghem W, von Behren V, et al. Addition of eplerenone to calcium channel blockers and beta blockers improves blood pressure control [abstract]. Eighteenth Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 14\u201317, 2003, New York, NY","DOI":"10.1016\/S0895-7061(03)00432-1"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870303007798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870303007798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:03:32Z","timestamp":1757567012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870303007798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0002870303007798"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2003.10.034","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2003.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}